Agios Pharm Stock Buy Hold or Sell Recommendation
| AGIO Stock | USD 31.81 1.60 5.30% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Agios Pharm is 'Strong Buy'. Macroaxis provides Agios Pharm buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AGIO positions. The advice algorithm takes into account all of Agios Pharm's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Agios Pharm's buy or sell advice are summarized below:
Real Value 37.38 | Target Price 39 | Hype Value 31.99 | Market Value 31.81 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Agios Pharm given historical horizon and risk tolerance towards Agios Pharm. When Macroaxis issues a 'buy' or 'sell' recommendation for Agios Pharm, the advice is generated through an automated system that utilizes algorithms and statistical models.
Agios |
Execute Agios Pharm Buy or Sell Advice
The Agios recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Agios Pharm. Macroaxis does not own or have any residual interests in Agios Pharm or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Agios Pharm's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Agios Pharm Trading Alerts and Improvement Suggestions
| Agios Pharm appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 26.82 M. Net Loss for the year was (352.09 M) with profit before overhead, payroll, taxes, and interest of 12.54 M. | |
| Agios Pharm currently holds about 819.31 M in cash with (296.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.95. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 17018 shares by Goff Brian of Agios Pharm subject to Rule 16b-3 |
Agios Pharm Returns Distribution Density
The distribution of Agios Pharm's historical returns is an attempt to chart the uncertainty of Agios Pharm's future price movements. The chart of the probability distribution of Agios Pharm daily returns describes the distribution of returns around its average expected value. We use Agios Pharm price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Agios Pharm returns is essential to provide solid investment advice for Agios Pharm.
| Mean Return | 0.57 | Value At Risk | -3.27 | Potential Upside | 7.26 | Standard Deviation | 3.04 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Agios Pharm historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Agios Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Agios Pharm's institutional investor refers to the entity that pools money to purchase Agios Pharm's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2023-12-31 | 1.6 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2023-12-31 | 1.6 M | Geode Capital Management, Llc | 2023-12-31 | 1.3 M | Goldman Sachs Group Inc | 2023-12-31 | 1.2 M | Deep Track Capital, Lp | 2023-12-31 | 1.1 M | Bnp Paribas Investment Partners Sa | 2023-12-31 | 1 M | Pictet Asset Manangement Sa | 2023-12-31 | 958.3 K | T. Rowe Price Investment Management,inc. | 2023-12-31 | 929.9 K | Fisher Asset Management, Llc | 2023-12-31 | 711.5 K | Vanguard Group Inc | 2023-12-31 | 5.5 M | Blackrock Inc | 2023-12-31 | 5 M |
Agios Pharm Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 10.4M | 46.5M | 75.7M | (63.9M) | (51.1M) | (48.5M) | |
| Free Cash Flow | (382.8M) | (305.7M) | (413.1M) | (314.4M) | (297.1M) | (311.9M) | |
| Depreciation | 8.1M | 10.0M | 9.2M | 8.6M | 6.6M | 5.9M | |
| Other Non Cash Items | 8.5M | 19.5M | 9.5M | (119.1M) | 101.6M | 106.7M | |
| Capital Expenditures | 12.2M | 14.9M | 5.7M | 4.9M | 999K | 949.1K | |
| Net Income | (411.5M) | (327.4M) | (356.5M) | (231.8M) | (352.1M) | (334.5M) | |
| End Period Cash Flow | 80.9M | 127.4M | 203.1M | 139.3M | 88.2M | 113.3M | |
| Change To Netincome | 73.4M | 75.1M | (39.7M) | 49.2M | 56.6M | 39.0M | |
| Change To Inventory | (6.5M) | (7.4M) | 4.4M | (8.5M) | (10.6M) | (10.1M) | |
| Investments | 103.6M | 90.7M | (548.4M) | 243.3M | 239.6M | 251.6M |
Agios Pharm Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Agios Pharm or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Agios Pharm's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Agios stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.41 | |
β | Beta against NYSE Composite | 1.94 | |
σ | Overall volatility | 3.00 | |
Ir | Information ratio | 0.16 |
Agios Pharm Volatility Alert
Agios Pharm has relatively low volatility with skewness of 1.59 and kurtosis of 3.41. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Agios Pharm's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Agios Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Agios Pharm Fundamentals Vs Peers
Comparing Agios Pharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Agios Pharm's direct or indirect competition across all of the common fundamentals between Agios Pharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Agios Pharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Agios Pharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Agios Pharm by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Agios Pharm to competition |
| Fundamentals | Agios Pharm | Peer Average |
| Return On Equity | -0.37 | -0.31 |
| Return On Asset | -0.22 | -0.14 |
| Operating Margin | (14.96) % | (5.51) % |
| Current Valuation | 992.71 M | 16.62 B |
| Shares Outstanding | 56.19 M | 571.82 M |
| Shares Owned By Insiders | 1.61 % | 10.09 % |
| Shares Owned By Institutions | 98.39 % | 39.21 % |
| Number Of Shares Shorted | 6.6 M | 4.71 M |
| Price To Earning | 1.26 X | 28.72 X |
| Price To Book | 2.05 X | 9.51 X |
| Price To Sales | 61.82 X | 11.42 X |
| Revenue | 26.82 M | 9.43 B |
| Gross Profit | 12.54 M | 27.38 B |
| EBITDA | (384.86 M) | 3.9 B |
| Net Income | (352.09 M) | 570.98 M |
| Cash And Equivalents | 819.31 M | 2.7 B |
| Cash Per Share | 14.95 X | 5.01 X |
| Total Debt | 72 M | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 17.98 X | 2.16 X |
| Book Value Per Share | 14.50 X | 1.93 K |
| Cash Flow From Operations | (296.06 M) | 971.22 M |
| Short Ratio | 9.54 X | 4.00 X |
| Earnings Per Share | (6.33) X | 3.12 X |
| Target Price | 42.8 | |
| Number Of Employees | 383 | 18.84 K |
| Beta | 0.86 | -0.15 |
| Market Capitalization | 1.7 B | 19.03 B |
| Total Asset | 937.12 M | 29.47 B |
| Retained Earnings | (822.65 M) | 9.33 B |
| Working Capital | 765.88 M | 1.48 B |
| Current Asset | 337.33 M | 9.34 B |
| Current Liabilities | 52.89 M | 7.9 B |
Note: Disposition of 17018 shares by Goff Brian of Agios Pharm subject to Rule 16b-3 [view details]
Agios Pharm Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Agios . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 97230.01 | |||
| Daily Balance Of Power | 0.6107 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 31.71 | |||
| Day Typical Price | 31.74 | |||
| Price Action Indicator | 0.9 | |||
| Period Momentum Indicator | 1.6 |
About Agios Pharm Buy or Sell Advice
When is the right time to buy or sell Agios Pharm? Buying financial instruments such as Agios Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 32.0M | 30.4M | 43.2M | 29.6M | Total Assets | 1.4B | 1.2B | 937.1M | 752.6M |
Use Investing Ideas to Build Portfolios
In addition to having Agios Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sports Thematic Idea Now
Sports
Companies in sporting activities arena as well as manufacturers of sporting goods and sport retailers. The Sports theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sports Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Agios Pharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Agios Stock analysis
When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.33) | Revenue Per Share 0.482 | Quarterly Revenue Growth 0.648 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.